Search

Displaying results 1431 - 1440 of 8575 in total
  1. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

  2. Drug

    Thiotepa

    go.drugbank.com/drugs/DB04572
    ApprovedInvestigational

    It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

    Products: TEPADINA 400MG
  3. Drug

    Pentetic acid

    go.drugbank.com/drugs/DB14007
    ApprovedInvestigational

    [L2242] DPTA was developed by the pharmaceutical company CIS US and FDA approved on April 14, 2004.[L1469] … [A32501] It is currently considered, in all the dosage forms, as a member of the list of approved inactive ingredients for drug products by the FDA.

  4. Drug

    Molindone

    go.drugbank.com/drugs/DB01618
    Approved

    Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. … It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors.

  5. Drug

    Fremanezumab

    go.drugbank.com/drugs/DB14041
    ApprovedInvestigational

    [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. … [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment

  6. Drug

    Thiosulfuric acid

    go.drugbank.com/drugs/DB09499
    ApprovedInvestigational

    [A252827] Sodium thiosulfate is rapidly degraded in the stomach; therefore, it is normally administered through other routes, such as intravenous or topical. … Sodium thiosulfate is part of the World Health Organization’s list of essential medicines, and it has a variety of industrial uses, including food preservative, water de-chlorinator and paper pulp bleaching

  7. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.

  8. Drug

    Levosalbutamol

    go.drugbank.com/drugs/DB13139
    Approved

    [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. … The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol

  9. Drug

    Pentoxyverine

    go.drugbank.com/drugs/DB11186
    ApprovedWithdrawn

    Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate. … Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant [A32717], and local anesthetic properties.

  10. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    It has one chiral center and is the R-stereoisomer.[L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … [L54141] Nerandomilast exerts both anti-fibrotic and immunomodulatory effects as PDE4 inhibition elevates intracellular cAMP levels and reduces the expression of pro-fibrotic growth factors and inflammatory